Physician profile
Patrick Beer
NPI 1861733123
$4,477.94
in general payments reported to CMS, 2019-2025
14 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Trauma Surgery provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $3,200 · 2023: $227 · 2024: $150 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,619.94 | 2021-2024 | |
| Smith+Nephew, INC. | $482.03 | 2021-2025 | Oasis, Collagenase Santyl, Grafix |
| Globus Medical, INC. | $450.87 | 2022 | |
| Integra Lifesciences Corporation | $248.30 | 2021-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Avita Medical Americas, LLC | $176.35 | 2024-2025 | Recell, Permeaderm, Cohealyx |
| Medtronic, INC. | $139.40 | 2021-2023 | V-Loc 180, Signia |
| Ethicon US, LLC | $139.21 | 2021-2022 | |
| Access Pro Medical, LLC | $72.71 | 2025 | Matriderm |
| Kerecis Limited | $31.98 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Polynovo North America LLC | $30.54 | 2024 | Novosorb Btm |
| Mimedx Group, INC. | $22.84 | 2025 | |
| Vericel Corporation | $22.60 | 2025 | Nexobrid |
| Sanara Medtech INC. | $21.05 | 2025 | Celleraterx |
| Vertex Pharmaceuticals Incorporated | $20.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Beer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.